The digital solution

A fresh breath for many patients

The digital innovation Kata® enables a new, significantly higher therapy standard for chronic respiratory diseases. It supports patients during inhalation therapy to reduce application errors with inhalers and to improve the success of therapy.

The team of specialists from the German company VisionHealth GmbH has thus achieved a worldwide revolutionary improvement in the inhalation treatment of pneumological diseases.

Digitally against asthma and COPD

The technologies used in Kata® help those affected to improve the handling of all common inhalation devices as part of their inhalation therapy. The specially developed inhalation trainer consists of a combination of visual aids for correct application (Augmented Reality), machine learning (Artificial Intelligence) and the documentation of the results in a diary. The administration of active substances or medication can be significantly optimized and treatment and therapy successes improved.

Prescription for sustainably better patient care

Kata® also provides pneumologists with a completely new type of digital inhalation assistant that can reduce the treatment effort of their patients and sustainably improve their care.

  • The therapeutic potential of Kata® is very high for a large number of patients with asthma or COPD. The Kata® technology is based on many years of experience and deep knowledge of the frequent application errors of patients. This is where App Kata® can offer real added value for patients, relatives and treating physicians. Digital therapy support will become increasingly important in the healthcare sector in the future and will soon be part of everyday practice and clinical routine. VisionHealth has recognized this need and has put together an outstanding team that can contribute its profound experience in respiratory diseases, existing therapy approaches and industry.

    Dr. Georg Matheis
    Dr. Georg Matheis Physician and entrepreneur
  • When I heard about VisionHealth and Kata, I immediately became curious. Since I then tried the app, I don't want to miss it anymore. I have a much better quality of life than before! I am an enthusiastic biker and don't have to do without it, as long as I do lung exercises and take medication courageously. Like a good friend, Kata reminds me and measures how successful I used my spray.

    Frank Hennemann
    Frank Hennemann Motorcyclist and patient with Alpha-1-Antitrypsin Deficiency

What Kata® offers

Personalized digital assistant for asthma and COPD patients. Trains the best possible therapy efficiency.

Real-time training for patients during daily use. Ensures an appropriate, reproducible dose in the lungs for effective treatment.

Transversal use, adapted to all inhaler types. Does not require expensive and cumbersome adjustments of hardware components.

Daily symptom and therapy records. Allows physicians to make well-informed therapy decisions.

Reports on disease progression and adherence by Kata®. Enable patients to monitor their medication and detect subtle changes.

Collection of anonymised data by Kata®. Supports the optimisation of the respective medication and methodology.

Doctors and patients on board with Kata® right from the start

In developing Kata® from the very beginning, the involvement of stakeholders and experts was a priority. In this way it is possible to find out what patients actually dislike about their illness and what really supports them.

Expert advisory board

We have been developing our products from the very beginning with the support of experts: patients and doctors.

Dr. Peter Haidl

Chief of pneumology

Specialist hospital Kloster Grafschaft GmbH

Academic Teaching Hospital of the Philipps University of Marburg

Frank Hennemann

Patient relations manager

Pharmaceutical and health advisors

Patient with Alpha1-Antitrypsin-Deficiency

Dr. Klaus Klütsch

Internist Pneumology

DMP training for  asthma and COPD

Supervision of lung sports groups

Ulrike Nowak

Health scientist

Medical assistant

Asthmatic patient

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 867249.

Feel free to contact us

Just send us a message and we will get back to you as soon as possible.

Not readable? Change text. captcha txt